This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Prima BioMed Ltd.
Drug Names(s): IMP321, IMP-321, ImmuFact IMP-321, EDP202, EDP-202, mLAG-31g
Description: ImmuFact IMP321 is a highly potent T cell immunostimulatory factor. It is a recombinant soluble human Lymphocyte Activation Gene-31g (LAG-3) fusion protein, LAG-3 is a transmembrane CD4-related protein expressed transiently on activated T cells. LAG-3 binds, with high affinity, to MHC class II molecules expressed by dendritic cells and monocytes. This binding leads to dendritic cells maturation, migration to the lymph nodes and enhanced cross-presentation of antigens to T cells.
Immutep and Eddingpharm
In October 2013, Immutep and Eddingpharm entered into an agreement regarding the development, commercialization and manufacturing of Immuteps ImmuFact IMP321. Financial details are undisclosed but include milestone payments and royalties.
The agreement grants Eddingpharm exclusive rights to develop and market IMP321 in mainland China, Hong Kong, Macau and Taiwan. Immutep will provide full technical support for the development of the product.
Prima and Immutep
In October 2014, Prima BioMed announced that it has reached an agreement to acquire Immutep SA. Prima will pay consideration of up to approximately US$28 M through a combination of cash, shares and warrants subject to the achievement of certain performance milestones.
In December 2014, Prima BioMed announced that the acquisition of Immutep SA (Immutep) has been completed.
Prima, NEC, and Yamaguchi
In May 2015, Prima BioMed announced a...See full deal structure in Biomedtracker
ImmuFact IMP321 News
Additional information available to subscribers only: